Who Owns Revvity Company?

Who Owns Revvity?

Revvity, Inc. emerged from a significant corporate separation from its predecessor, PerkinElmer, Inc., in 2022 and 2023. This strategic move divided the life sciences and diagnostics operations into Revvity, while other segments were sold.

Understanding Revvity's ownership is key to grasping its strategic direction and accountability. The company officially launched as Revvity on May 9, 2023, with its stock symbol RVTY replacing PKI on May 16, 2023.

Revvity, founded in 1937 and headquartered in Waltham, Massachusetts, is a public company. As of December 29, 2024, it employed approximately 11,000 people globally and reported a fiscal year 2024 revenue of $2.755 billion. The company's offerings include solutions for research and diagnostics, such as reagents and instruments, supporting areas like genomics and Revvity BCG Matrix analysis.

Revvity's lineage traces back to PerkinElmer, established in 1937. While precise details of the original founders' equity stakes are not publicly detailed, the company's extensive history under the PerkinElmer name signifies a foundational period predating its current identity. The transition to Revvity in 2023 was a strategic spin-off, meaning the concept of 'founding ownership' for Revvity largely pertains to the ownership structure immediately following this separation from its former parent company.

Origins of Revvity

Revvity's history is deeply intertwined with PerkinElmer, founded in 1937. This long-standing heritage forms the bedrock of the company's evolution.

Founding Ownership Details

Specifics regarding the initial equity distribution among PerkinElmer's founders are not readily available. The focus shifts to the ownership structure post-spin-off for Revvity.

Revvity's Spin-Off

The establishment of Revvity in 2023 was a result of a strategic spin-off from PerkinElmer. This event marked a new chapter in its ownership landscape.

Early Ownership Context

The term 'founding ownership' for Revvity primarily refers to the ownership dynamics that emerged immediately after its separation from PerkinElmer.

PerkinElmer's Legacy

The foundational period of PerkinElmer laid the groundwork for the eventual creation of Revvity. Understanding this history is key to grasping Revvity's corporate structure.

Revvity's Corporate Evolution

Revvity Inc. emerged as a distinct entity through a strategic corporate maneuver. This spin-off created a new ownership framework for the business segments involved.

Understanding Revvity's Ownership Structure

The ownership of Revvity is primarily shaped by its recent spin-off from PerkinElmer. This strategic separation means that the initial ownership structure of Revvity is tied to how the shares were distributed to PerkinElmer shareholders at the time of the spin-off.

• The spin-off event in 2023 created Revvity as a separate, publicly traded company.
• Shareholders of PerkinElmer at the time of the spin-off received shares in Revvity.
• This distribution determined the initial public ownership breakdown of Revvity.
• Key shareholders of Revvity company would therefore include institutional investors and individual investors who were previously shareholders of PerkinElmer.
• Further details on Revvity investor relations information can provide a more granular look at current stock ownership.
• The Target Market of Revvity is served by its distinct business segments, each contributing to the overall company value.

Complete Revvity Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

Revvity's ownership structure was significantly reshaped by its separation from PerkinElmer, becoming an independent public entity. This transition, completed in 2023, established its current trading status on the NYSE, influencing who owns Revvity and its strategic direction.

Revvity operates as a public company, with its shares traded on the New York Stock Exchange under the ticker RVTY since May 16, 2023. This followed its spin-off from PerkinElmer, marking a significant point in its Revvity history. As of July 28, 2025, the company had 120,147,286 shares of common stock outstanding. The majority of Revvity's ownership, approximately 95.01% as of July 28, 2025, is held by institutional investors. These entities, numbering 1,066 as of the same date, collectively held 138,097,399 shares, indicating a broad base of institutional support. The market capitalization of Revvity stood at $14.5 billion as of October 29, 2024. For the fiscal year 2024, Revvity reported revenue of $2.755 billion, a slight increase from $2.751 billion in 2023, with a GAAP operating income of $347 million in 2024. Understanding the Mission, Vision & Core Values of Revvity can provide further context to its strategic direction and stakeholder alignment.

Key Shareholders Driving Revvity's Ownership

Institutional investors are the dominant force in Revvity's shareholder base, holding over 95% of the company's stock. This concentration of ownership by large financial firms signifies substantial influence on corporate governance and strategic decisions.

• T. Rowe Price Investment Management Inc. is a leading shareholder.
• Vanguard Group Inc. also holds a significant stake.
• BlackRock, Inc. is among the major institutional owners.
• The collective holdings underscore the importance of institutional investor relations for Revvity.

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

Revvity's governance is guided by a Board of Directors, with Prahlad Singh serving as President and CEO. Other directors include Peter Barrett, Samuel R. Chapin, Michael A. Klobuchar, Michelle McMurry-Heath, Michel Vounatsos, Sophie V. Vandebroek, Frank Witney, and Pascale Witz. Alexis Michas holds the position of Independent Non-Executive Chairman. The average tenure on the board is 6.8 years.

Revvity operates under a straightforward voting structure where each share of common stock grants one vote. There is no provision for cumulative voting. As of February 25, 2025, the company had 120,147,286 shares of common stock outstanding and eligible to vote. The company's proxy statement, issued on March 12, 2025, for the 2025 annual shareholder meeting, details the board's recommendations on key proposals, including director elections and a proposed amendment to governance documents to adopt a majority voting standard for certain corporate actions.

Understanding Revvity's Voting Power

Revvity's corporate governance emphasizes a one-share-one-vote principle, ensuring that each share holds equal voting weight. This structure is fundamental to how shareholders influence company decisions.

• One-share-one-vote principle is applied.
• No cumulative voting is in place.
• As of February 25, 2025, there were 120,147,286 voting shares.
• Board recommendations are detailed in the proxy statement.
• A proposal to amend governance documents for majority voting standards is noted.

Revvity Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

Revvity has experienced significant shifts in its ownership structure and strategic direction over the past few years, most notably its spin-off from PerkinElmer in 2023. This strategic maneuver was designed to sharpen focus on its life sciences and diagnostics operations, aiming for enhanced profitability and growth. The company has since been active in consolidating its market presence through strategic investments and acquisitions, with the $5.3 billion acquisition of BioLegend in 2021 being a key milestone prior to its rebranding.

Institutional investors maintain a dominant stake in Revvity, holding approximately 95.01% of the company's shares as of late July 2025. This strong institutional backing underscores confidence in the company's strategic path. Revvity has actively engaged in share repurchase programs, demonstrating a commitment to returning value to shareholders, with buybacks amounting to $153.57 million by March 31, 2025, and $181.72 million by December 31, 2024. Despite these efforts, some market observers have voiced concerns regarding the allocation of capital and the pace of business performance recovery in the post-pandemic environment, even as the company works to reduce its debt load.

Strategic Spin-off and Focus

The 2023 spin-off from PerkinElmer marked a pivotal moment for Revvity. This move allowed for a more concentrated approach on its life sciences and diagnostics segments, aiming to unlock greater growth potential and improve profit margins.

Key Acquisition and Expansion

The acquisition of BioLegend for $5.3 billion in 2021 was a significant step in bolstering Revvity's capabilities. This strategic move predated the company's rebranding and aimed to strengthen its position within the competitive life sciences market.

Financial Outlook and Growth Initiatives

Revvity has projected its full-year 2025 revenue to be between $2.84 billion and $2.88 billion, anticipating organic growth of 2% to 4%. The company is actively pursuing partnerships and collaborations to broaden its market reach and capitalize on emerging technological advancements.

Market Performance and Analyst Views

While Revvity has focused on debt reduction and share buybacks, some analysts have raised questions about capital allocation efficiency and business performance trends. Understanding the Competitors Landscape of Revvity is crucial when evaluating these trends.

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE